Cardiovascular Clinical Trials

Statistical methods in cardiovascular trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All cardiovascular trials

965 results

• EVERZOTAIndependent statistical analysis of Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 461NCT01347554
• EVITAIndependent statistical analysis of 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance…Phase 4Results postedn = 71NCT01169701
• EVITAIndependent statistical analysis of Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 302NCT00794573
• EvKIndependent statistical analysis of Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 801NCT02643381
• EVOLVE48Independent statistical analysis of A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 100NCT03350542
• EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia: Complete Statistical AnalysisIndependent statistical analysis of EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 70NCT00187889
• EXCELIndependent statistical analysis of Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 112NCT00579254
• Exercise for Swallowing Problems After Stroke: Complete Statistical AnalysisIndependent statistical analysis of Exercise for Swallowing Problems After Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00722111).Phase NAResults postedn = 83NCT00722111
• Exercise Pulmonary Transit Time: Complete Statistical AnalysisIndependent statistical analysis of Exercise Pulmonary Transit Time: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04336995).Phase 4Results postedn = 14NCT04336995
• Exercise Training in Heart Failure: Changes in Cardiac Structure and Function: Complete Statistical AnalysisIndependent statistical analysis of Exercise Training in Heart Failure: Changes in Cardiac Structure and Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 11NCT02275819
• Expiratory Muscle Training in Stroke: Complete Statistical AnalysisIndependent statistical analysis of Expiratory Muscle Training in Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04569968).Phase NAResults postedn = 146NCT04569968
• Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities: Complete Statistical AnalysisIndependent statistical analysis of Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 41NCT04572893
• EXSCELA detailed independent statistical analysis of EXSCEL, the phase 3 trial of exenatide once weekly versus placebo in patients with type 2 diabetes mellitus, including its randomized design, time-to-event endpoints, Cox models,…Phase 3Results postedn = 14,752NCT01144338
• EXT-HFIndependent statistical analysis of Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 65NCT03648762
• EXTENDAn independent statistical analysis of the EXTEND phase 3 trial of alteplase versus placebo in stroke, covering its randomized design, 3-month modified Rankin Scale endpoint, planned statistical analysis, and interpretation.Phase 3n = 180NCT00887328
• EXTENDIndependent statistical analysis of Expanding Technology-Enabled Nurse Delivered Chronic Disease Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05120544).Phase NAResults postedn = 220NCT05120544
• EXTEND-IAIndependent statistical analysis of EXTEND-IA, a randomized phase 2 trial comparing tenecteplase with tissue plasminogen activator before endovascular therapy for ischemic stroke.Phase 2n = 202NCT02388061
• Extension Study of IMO-8400 in Patients With Waldenström’s Macroglobulinemia Who Completed Study 8400-401: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 5NCT02363439
• EXTRA-CVDIndependent statistical analysis of A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 298NCT03643705
• FAIR-HFAn independent statistical analysis of the randomized phase 3 FAIR-HF trial evaluating ferric carboxymaltose versus normal saline in patients with chronic heart failure and iron deficiency.Phase 3n = 456NCT00520780
• Fall-recovery Training for Those With Chronic Stroke and Low Falls Self-efficacy: Complete Statistical AnalysisIndependent statistical analysis of Fall-recovery Training for Those With Chronic Stroke and Low Falls Self-efficacy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 1NCT04112173
• FAME 2Independent statistical analysis of FAME 2, the NCT06159231 10-year follow-up study in coronary artery disease, focusing on the 10-year major adverse cardiac event endpoint and its appropriate statistical interpretation.n = 888NCT06159231
• FAME 3Independent statistical analysis of A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease: primary endpoint results, effect estimate with…Phase NAResults postedn = 1,500NCT02100722
• FAME II – Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT: Complete Statistical AnalysisIndependent statistical analysis of FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 1,170NCT01132495
• FAST PV and mGFR™ Technology in Congestive Heart Failure: Complete Statistical AnalysisIndependent statistical analysis of FAST PV and mGFR™ Technology in Congestive Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03808948).Phase NAResults postedn = 50NCT03808948
• FASTIIIndependent statistical analysis of Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 112NCT03635190
• FAVORITComplete statistical analysis of FAVORIT, a randomized phase 2/3 trial evaluating high-dose versus low-dose multivitamins in kidney transplant recipients with cardiovascular disease risk.Phase 2/3Results postedn = 4,110NCT00064753
• Feasibility of Measuring Vertical Perception in Acute Stroke: Complete Statistical AnalysisIndependent statistical analysis of Feasibility of Measuring Vertical Perception in Acute Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06301815).Phase NAResults postedn = 53NCT06301815
• Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms: Complete Statistical AnalysisIndependent statistical analysis of Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 31NCT02021812
• FEAStIndependent statistical analysis of Fostering Eating After Stroke With Transcranial Direct Current Stimulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01919112).Phase NAResults postedn = 42NCT01919112
• Fibrin Sealant Vascular Surgery Study: Complete Statistical AnalysisIndependent statistical analysis of Fibrin Sealant Vascular Surgery Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00576420).Phase 2Results postedn = 101NCT00576420
• FIGARO-DKDIndependent statistical analysis of FIGARO-DKD, a randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.Phase 3Results postedn = 7,352NCT02545049
• Figure 8Independent statistical analysis of Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 70NCT03040661
• FINEARTS-HFIndependent statistical analysis of FINEARTS-HF, the randomized phase 3 trial evaluating finerenone versus placebo in participants with heart failure and left ventricular ejection fraction greater than or equal to 40%.Phase 3Results postedn = 6,016NCT04435626
• First – In – Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism: Complete Statistical AnalysisIndependent statistical analysis of First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism: primary endpoint results, effect…Phase 1Results postedn = 9NCT03927508
• First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone: Complete Statistical AnalysisIndependent statistical analysis of First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone: primary endpoint results, effect estimate with confidence interval,…Phase 1Results postedn = 10NCT04075721
• First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study: Complete Statistical AnalysisIndependent statistical analysis of First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study: primary endpoint…Phase 4Results postedn = 458NCT01419249
• Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 200NCT01977794
• FLAXPADIndependent statistical analysis of Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2/3Results postedn = 110NCT00781950
• Fluid Balance in the ICU – Interventions to Minimize Fluids in Patients With Septic Shock: Complete Statistical AnalysisIndependent statistical analysis of Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 82NCT02473718
• FLUORESCEIndependent statistical analysis of Fluoxetine for Visual Recovery After Ischemic Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02737930).Phase 2Results postedn = 17NCT02737930
• FOCUSComplete statistical analysis of the FOCUS randomized phase 3 trial comparing liberal and restrictive blood transfusion strategies in surgical patients with cardiovascular disease, including endpoint definitions, reported odds ratios and risk differences,…Phase 3Results postedn = 2,016NCT00071032
• FOCUSIndependent statistical analysis of A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 315NCT01302392
• FOCUS HFA detailed statistical analysis of the randomized phase 1 FOCUS HF trial evaluating intramyocardial injection of autologous bone-marrow stem cells via NOGA mapping in patients with ischemic cardiomyopathy, including its crossover design,…Phase 1Results postedn = 30NCT00203203
• Forced-air Warming in Endovascular Surgery: Testing Effectiveness of Two Different Blanket Models: Complete Statistical AnalysisIndependent statistical analysis of Forced-air Warming in Endovascular Surgery: Testing Effectiveness of Two Different Blanket Models: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 50NCT02742818
• FOURIER-OLEAn independent statistical analysis and educational interpretation of FOURIER-OLE, a phase 3 open-label extension study of evolocumab in participants with dyslipidemia.Phase 3Results postedn = 5,035NCT02867813
• FREEDOMIndependent statistical analysis of the FREEDOM trial comparing coronary artery bypass grafting with percutaneous coronary intervention in individuals with diabetes and multivessel coronary artery disease, including time-to-event methods, reported results, safety, and…Phase 3Results postedn = 1,900NCT00086450
• FRESHIndependent statistical analysis of FimasaRtan-basEd BP Targets After Drug SwitcHing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03649646).Phase NAResults postedn = 4,542NCT03649646
• Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006): Complete Statistical AnalysisIndependent statistical analysis of Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 22NCT04370873
• FROZEN-AFIndependent statistical analysis of Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 458NCT04133168

← All therapeutic areas